Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Recruiting now
Conditions studied: Diagnosed or Relapsed/Refractory Sarcomas
In brief
Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.
Key facts
- Study ID
- NCT04621201
- Run by
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
- People needed
- 120
- Starts
- 2018-12-06
- Expected to finish
- 2026-12-06
- Last updated by the study team
- 2023-03-29
Who can join
Age: any, up to 24. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis.
- Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma
- Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample.
- Patients aged ≤24 years
- Pathological review of tumor samples.
- Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional.
You may not qualify if…
- 1. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.
Where it is running
- IRCCS materno infantile Burlo Garofolo — Trieste, Italy (enrolling)
- Istituto Ortopedico Rizzoli — Bologna, Italy (enrolling)
- Policlinico S.Orsola-Malpighi — Bologna, Italy (enrolling)
- Azienda ospedaliero-universitaria Meyer — Florence, Italy (enrolling)
- Istituto Giannina Gaslini — Genova, Italy (enrolling)
- Istituto Nazionale Tumori — Milan, Italy (enrolling)
- Fondazione I.R.C.C.S. Policlinico San Matteo — Pavia, Italy (enrolling)
- AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita — Torino, Turin, Italy (enrolling)
- Presidio Ospedaliero Gaetano Pini | ASST Pini-CTO — Milan, Italy
- Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena e Istituto Dermatologico San Gallicano — Roma, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.